GlassScriptPhysician profile
Jennifer S Kloth
NPI 1194965939
$2,255.01
in general payments reported to CMS, 2019-2025
35 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $282 · 2022: $1,039 · 2023: $605 · 2024: $208 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $891 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $890.76 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $529.19 | 2022-2023 | Padcev |
| Novartis Pharmaceuticals Corporation | $234.37 | 2021-2024 | |
| Adaptive Biotechnologies Corporation | $164.87 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $100.99 | 2022-2025 | Enhertu |
| Emd Serono, INC. | $95.70 | 2023-2025 | Bavencio |
| E.R. Squibb & Sons, L.L.C. | $92.33 | 2022-2023 | Opdivo |
| Takeda Pharmaceuticals U.S.A., INC. | $87.89 | 2022-2024 | Fruzaqla, Alunbrig, Iclusig |
| Eisai INC. | $82.94 | 2021-2023 | |
| Pfizer INC. | $82.82 | 2021-2024 | |
| Celgene Corporation | $80.27 | 2023-2024 | Reblozyl, Opdualag |
| Genentech USA, INC. | $71.47 | 2022-2023 | Tecentriq, Venclexta |
| Abbvie INC. | $65.17 | 2021-2023 | |
| Amgen INC. | $52.72 | 2022 | |
| Merck Sharp & Dohme LLC | $49.76 | 2021-2023 | Keytruda |
| Myriad Genetic Laboratories, INC. | $49.23 | 2022-2023 | Myrisk |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $42.52 | 2021-2023 | |
| Kite Pharma, INC. | $42.49 | 2021-2023 | Yescarta |
| Puma Biotechnology, INC. | $31.91 | 2021 | |
| Glaxosmithkline, LLC. | $30.06 | 2021-2023 | Ojjaara |
| Menarini Silicon Biosystems, INC. | $21.12 | 2024 | |
| Adc Therapeutics America, INC. | $20.90 | 2022 | |
| Genzyme Corporation | $20.04 | 2023 | |
| Genmab U.S., INC. | $19.92 | 2021 | |
| Springworks Therapeutics, INC. | $19.34 | 2024 | Ogsiveo |
| Astellas Pharma US INC | $17.70 | 2023 | |
| Geron Corporation | $17.68 | 2025 | Rytelo |
| Sumitomo Pharma America, INC. | $17.05 | 2023 | Orgovyx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.66 | 2021 | |
| Array Biopharma INC | $15.95 | 2023 | Braftovi, Lorbrena, Xalkori |
| Bayer Healthcare Pharmaceuticals INC. | $14.91 | 2023 | |
| Janssen Biotech, INC. | $14.56 | 2021 | |
| Epizyme, INC. | $14.39 | 2022 | |
| Daiichi Sankyo INC. | $12.85 | 2023 | Enhertu |
| Aveo Pharmaceuticals, INC. | $12.83 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $12.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Kloth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.